Serum Proteomic Profiling in Patients with Bladder Cancer

European Urology

Volumn 56, Issue 6, 2009, Pages 989-997

  Schwamborn, Kristina ^a   Krieg, René C ^a   Grosse, Joachim ^a   Reulen, Nadine ^a   Weiskirchen, Ralf ^a   Knuechel, Ruth ^a   Jakse, Gerhard ^a   Henkel, Corinna ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Bladder cancer; MALDI; Mass spectrometry; Pattern profiling; Proteomics; Serum

Indexed keywords

PLASMA PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; FEMALE; HUMAN; MAGNET; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

AGED; ALGORITHMS; FEMALE; HUMANS; MAGNETICS; MALE; MICROSPHERES; MIDDLE AGED; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SOFTWARE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 70350566688     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.02.031     Document Type: Article

References (30)

1. Stewart BW, Kleihues P. World Cancer Report. Lyon, France: IARC Press; 2003.
2. Oosterlinck W., Lobel B., Jakse G., Malmström P.-U., Stöckle M., Sternberg C., and The EAU Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 41 (2002) 105-112
3. Konety B.R. Molecular markers of bladder cancer: a critical appraisal. Urol Oncol 24 (2006) 326-337
4. Zaak D., Kriegmair M., Stepp H., et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 57 (2001) 690-694
5. Kriegmair M., Baumgartner R., Knuechel R., et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 155 (1996) 101-110
6. Karakiewicz P.I., Benayoun S., Zippe C., et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. Br J Urol 97 (2006) 997-1001
7. Curry J.L., and Wojcik E.M. The effects of the current World Health Organization and International Society of Urologic Pathologists bladder neoplasm classification system in urine cytology results. Cancer 96 (2002) 140-145
8. Lokeshwar V.B., and Selzer M.G. Urinary bladder tumor markers. Urol Oncol 24 (2006) 528-537
9. Celis J.E., and Gromov P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3 (2003) 9-15
10. Munro N.P., Cairns D.A., Clarke P., et al. Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer 119 (2006) 2642-2650
11. Mueller J., von Eggeling F., Driesch D., Schubert J., Melle C., and Junker K. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur Urol 47 (2005) 885-894
12. Liu W., Guan M., Wu D., et al. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur Urol 47 (2005) 456-462
13. Zhang Y.F., Wu D.L., Guan M., et al. Tree analysis of mass spectral urine profilesdiscriminates transitional cell carcinoma of the bladder from noncancer patients. Clin Biochem 37 (2004) 772-779
14. Vlahou A., Giannopoulos A., Gregory B.W., et al. Protein profiling in urine for the diagnosis of bladder cancer. Clin Chem 50 (2004) 1438-1441
15. Vlahou A., Schellhammer P.F., Mendrinos S., et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 158 (2001) 1491-1502
16. Liotta L.A., and Kohn E.C. The microenvironment of the tumor-host interface. Nature 411 (2001) 375-379
17. van der Merwe D.E., Oikonomopoulou K., Marshall J., and Diamidis E.P. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv Cancer Res 96 (2007) 23-50
18. Vrooman O.P.J., and Witjes J.A. Urinary markers in bladder cancer. Eur Urol 53 (2008) 909-916
19. Alaiya A., Al-Mohanna M., and Linder S. Clinical cancer proteomics: promises and pitfalls. J Proteome Res 4 (2005) 1213-1222
20. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic pattern in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
21. Adam B.L., Qu Y., Davis J.W., et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62 (2002) 3609-3614
22. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., and Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48 (2002) 1296-1304
23. Coombes K.R., Morris J.S., Hu J., Edmonson S.R., and Baggerly K.A. Serum proteomics profiling-a young technology begins to mature. Nat Biotechnol 23 (2005) 291-292
24. Norden A.G., Rodriguez-Cutillas P., and Unwin R.J. Clinical urinary peptidomics: learning to walk before we can run. Clin Chem 53 (2007) 375-376
25. Schaub S., Wilkins J., Weiler T., Sangster K., Rush D., and Nickerson P. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 65 (2004) 323-332
26. Vorderwülbecke S., Cleverley S., Weinberger S.R., and Wiesner A. Protein quantification by the SELDI-TOF-MS-based ProteinChip® System. Nat Methods 2 (2005) 393-395
27. Fiedler G.M., Baumann S., Leichtle A., et al. Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 53 (2007) 421-428
28. Engwegen J.Y., Gast M.C., Schellens J.H., and Beijnen J.H. Clinical proteomics: searching for better tumor markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 27 (2006) 251-259
29. Baggerly K.A., Morris J.S., Edmonson S.R., and Coombes K.R. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 97 (2005) 307-309
30. Schiffer E., Mischak H., Theodorescu D., and Vlahou A. Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. World J Urol 26 (2008) 67-74